A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia |
| |
Authors: | Maryam Noroozian Sina Ghasemi Seyed-Mohammad-Reza Hosseini Amirhossein Modabbernia Mohammad-Reza Khodaie-Ardakani Omid Mirshafiee Mehdi Farokhnia Masih Tajdini Farzin Rezaei Bahman Salehi Mandana Ashrafi Habibeh Yekehtaz Mina Tabrizi Shahin Akhondzadeh |
| |
Affiliation: | 1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran 3. Razi Psychiatric Hospital, University of Social Welfare and Rehabilitation, Tehran, Iran 4. Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, Iran 5. Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran 6. Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran 2. Razi Psychiatric Hospital, Welfare Sciences University, Tehran, Iran
|
| |
Abstract: | Rational A growing body of evidence illustrates that 5-HT3 receptor antagonist drugs may be of benefit in the treatment of negative symptoms in schizophrenia. Objective The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia. Methods In a double-blind, placebo-controlled 8-week trial, 40 patients with chronic schizophrenia who were stabilized on risperidone were randomized into tropisetron or placebo add-on groups. Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) every 2 weeks. Furthermore, extrapyramidal and depressive symptoms as well as side effects were assessed. The primary outcome measure was the difference in change from baseline of negative subscale scores between the two groups at week 8. Results Tropisetron resulted in greater improvement of the total PANSS scores [F(1.860,70.699)?=?37.366, p?0.001] as well as negative scores [F(2.439,92.675)?=?16.623, p?0.001] and general psychopathology [F(1.767,67.158)?=?4.602, p?=?0.017], but not positive subscale scores [F(1.348, 51.218)?=?0.048, p?=?0.893] compared to placebo. In a multiple regression analysis controlling for positive, extrapyramidal, and depressive symptoms, treatment group (standardized β?=??0.640) significantly predicted changes in primary negative symptoms. The side effect profile did not differ significantly between the two groups. Conclusion Tropisetron add-on to risperidone improves the primary negative symptoms of patients with chronic stable schizophrenia. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|